The study highlights that patients with a subtype known as monocytic AML experience poorer outcomes ... Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia ...

"Patients with monocytic AML and no NPM1 mutation were ... correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study, Blood Cancer Discovery (2025).

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia ... called “monocytic,” had worse outcomes ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

An artificial intelligence (AI)-driven machine learning model was refined and validated internationally to accurately classify acute leukemia subtypes from routine laboratory data, according to Merlin ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid ...